Literature DB >> 21455665

Follow-up of pregnant women exposed to chicken pox: an audit of relationship between level of antibody and development of chicken pox.

E H Boxall1, P A C Maple, P Rathod, E Smit.   

Abstract

The purpose of this study was to validate through natural exposure a cut-off level of varicella zoster IgG as protective against infection with varicella zoster virus (VZV). Laboratory testing to determine VZV immune status of pregnant women exposed to varicella is recommended. Quantitative assays are now available which are sensitive and specific. More than 200 consecutive requests for screening in pregnant patients with recent varicella contacts were followed-up by questionnaire. DiaSorin LIAISON and VZV time resolved fluorescence immuno assay (VZV TRFIA) were used to measure VZV antibody level. One hundred fifty out of 209 (72%) questionnaires were returned; 14 patients developed varicella, 129 did not and seven were not known. Patients who had been given VZIG and developed varicella on follow-up had a mean antibody level before VZIG of 28 mIU/ml and 62 mIU/ml, by LIAISON and TRFIA, respectively. The mean IgG level of those that did not develop varicella was 885 and 866 mIU/ml by LIAISON and TRFIA, respectively. Those with levels <100 mIU/ml were more likely to develop chicken pox than those with levels >100 mIU/ml (relative risk of 10.4 for LIAISON and 8.8 for TRFIA). On the basis of the relatively small numbers in this study, quantitative assays, using a 100mIU/ml cut-off, can differentiate between those who are susceptible and those who are protected against exposure, however follow-up studies should include sampling for VZV DNA and IgM.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21455665     DOI: 10.1007/s10096-011-1211-4

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   5.103


  13 in total

1.  Identification of potential candidates for varicella vaccination by history: questionnaire and seroprevalence study.

Authors:  Eithne MacMahon; Lisa J Brown; Sarah Bexley; David C Snashall; Dipti Patel
Journal:  BMJ       Date:  2004-07-23

2.  Comparison of fifteen commercial assays for detecting Varicella Zoster virus IgG with reference to a time resolved fluorescence immunoassay (TRFIA) and the performance of two commercial assays for screening sera from immunocompromised individuals.

Authors:  P A Chris Maple; Annabel Gunn; Jane Sellwood; David W G Brown; Jim J Gray
Journal:  J Virol Methods       Date:  2008-11-28       Impact factor: 2.014

3.  Fetal varicella syndrome.

Authors:  A L Alkalay; J J Pomerance; D L Rimoin
Journal:  J Pediatr       Date:  1987-09       Impact factor: 4.406

4.  Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence.

Authors:  V Williams; A Gershon; P A Brunell
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

5.  Second varicella infections: are they more common than previously thought?

Authors:  Susan Hall; Teresa Maupin; Jane Seward; Aisha O Jumaan; Carol Peterson; Gary Goldman; Laurene Mascola; Melinda Wharton
Journal:  Pediatrics       Date:  2002-06       Impact factor: 7.124

6.  The cost-effectiveness of antenatal varicella screening with post-partum vaccination of susceptibles.

Authors:  A Pinot de Moira; W J Edmunds; J Breuer
Journal:  Vaccine       Date:  2005-10-03       Impact factor: 3.641

Review 7.  Varicella and the pregnant woman: prevention and management.

Authors:  Andrew J Daley; Susan Thorpe; Suzanne M Garland
Journal:  Aust N Z J Obstet Gynaecol       Date:  2008-02       Impact factor: 2.100

8.  Management of varicella contacts in pregnancy: VZIG or vaccination?

Authors:  Judith A Troughton; Grainne Crealey; Vivienne Crawford; Peter V Coyle
Journal:  J Clin Virol       Date:  2009-10-14       Impact factor: 3.168

9.  Performance of a time-resolved fluorescence immunoassay for measuring varicella-zoster virus immunoglobulin G levels in adults and comparison with commercial enzyme immunoassays and Merck glycoprotein enzyme immunoassay.

Authors:  P A C Maple; J Gray; J Breuer; G Kafatos; S Parker; D Brown
Journal:  Clin Vaccine Immunol       Date:  2006-02

10.  Evaluation of the time resolved fluorescence immunoassay (TRFIA) for the detection of varicella zoster virus (VZV) antibodies following vaccination of healthcare workers.

Authors:  S L R McDonald; P A C Maple; N Andrews; K E Brown; K L Ayres; F T Scott; M Al Bassam; A A Gershon; S P Steinberg; J Breuer
Journal:  J Virol Methods       Date:  2010-12-28       Impact factor: 2.014

View more
  2 in total

Review 1.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

2.  The differences in short- and long-term varicella-zoster virus (VZV) immunoglobulin G levels following varicella vaccination of healthcare workers measured by VZV fluorescent-antibody-to-membrane-antigen assay (FAMA), VZV time-resolved fluorescence immunoassay and a VZV purified glycoprotein enzyme immunoassay.

Authors:  P A C Maple; J Haedicke; M Quinlivan; S P Steinberg; A A Gershon; K E Brown; J Breuer
Journal:  Epidemiol Infect       Date:  2016-03-28       Impact factor: 2.451

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.